Enlivex reports positive interim data from ongoing Phase Ib clinical of “off-the-shelf” Allocetra
Enlivex Therapeutics (NASDAQ: ENLV), a Company focused on developing allogenic therapies for immune system rebalancing, announced positive interim efficacy data from its ongoing Phase Ib clinical trial in patients with severe sepsis. The analysis in based on data collated from 43 patients with severe sepsis,...
